Bristol-Myers Hit With False Marking Suit Over 3 Drugs

Law360, New York (November 19, 2010, 6:10 PM EST) -- Frequent qui tam plaintiff Promote Innovation LLC has accused Bristol-Myers Squibb Co. of marking its antibiotic Cefzil, its anti-anxiety medication Buspar and its cholesterol drug Pravachol with expired or inapplicable patents.

Bristol-Myers knowingly marked these accused products with three expired patents and one inapplicable patent that subsequently expired in order to deceive the public and gain a competitive advantage in the relevant marketplace, the plaintiff alleges in a complaint filed Thursday in the U.S. District Court for the Eastern District of Texas.

This false marking has...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.